How much revenue does Senzime AB (publ) make?

Senzime AB (publ) reported 104.02 million SEK in revenue for fiscal year 2025, up 77.9% from 58.48 million SEK in fiscal year 2024. In Q1 2026 revenue was 23.23 million SEK.

Where does Senzime AB (publ) make most of its revenue?

USA: 69% of revenue by region in fiscal year 2025, followed by Asia (16%).

What companies are similar to Senzime AB (publ)?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include C-Rad AB (publ) (CRAD-B.ST), Bactiguard Holding AB (publ) (BACTI-B.ST), FluoGuide A/S (FLUO.ST), OssDsign AB (publ) (OSSD.ST).

Senzime AB (publ) (SEZI.ST) Stock

About Senzime AB (publ)

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedan...

At a glance

Senzime AB (publ) reported revenue of 104.02 million SEK for fiscal year 2025, up 77.9% from fiscal year 2024, and net income of -137.42 million SEK. In Q1 2026 (the quarter ended March 31, 2026) revenue was 23.23 million SEK, down 1.1% from a year before. USA was its largest region in fiscal year 2025, with 69% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.